The estimated Net Worth of Raymond Joseph Hage is at least 674 千$ dollars as of 1 July 2009. Raymond Hage owns over 168,283 units of Novavax stock worth over 64,535$ and over the last 20 years Raymond sold NVAX stock worth over 609,335$.
Raymond has made over 3 trades of the Novavax stock since 2007, according to the Form 4 filled with the SEC. Most recently Raymond sold 168,283 units of NVAX stock worth 484,655$ on 1 July 2009.
The largest trade Raymond's ever made was selling 168,283 units of Novavax stock on 1 July 2009 worth over 484,655$. On average, Raymond trades about 20,878 units every 67 days since 2005. As of 1 July 2009 Raymond still owns at least 5,251 units of Novavax stock.
You can see the complete history of Raymond Hage stock trades at the bottom of the page.
Raymond's mailing address filed with the SEC is 115 APPLEGATE DRIVE, , WEST CHESTER, PA, 19382.
Over the last 23 years, insiders at Novavax have traded over 136,088,511$ worth of Novavax stock and bought 2,908,869 units worth 5,634,467$ . The most active insiders traders include David M Mott、Rajiv I. Modi、Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of 907,678$. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth 8,050$.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: